Search

everythinglearnresearchcommunity

for

Search:↓

14,15-EET may help reduce poststroke pain by affecting certain brain proteins.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.

Four-amino acid part makes enzyme sensitive to finasteride.

Loliolide can boost hair growth by activating specific cell pathways.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

JAK inhibitors offer new hope for treating severe alopecia areata.

New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

A woman developed severe kidney injury from using simvastatin with ciclosporin, highlighting the need for careful monitoring when combining these drugs.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.

JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.

Allopregnanolone is needed for certain brain processing issues caused by D1 dopamine receptor activation.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

JAK inhibitors are effective for hair regrowth in severe alopecia areata.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

Allopregnanolone can reduce gut inflammation and normalize neurotransmitter levels after finasteride withdrawal.

Ruxolitinib cream may help treat severe hair loss in children.

Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.

There is no significant link between alopecia areata and the PON1 enzyme polymorphisms studied.

New treatments for severe alopecia areata, especially JAK inhibitors, are recommended as first-line therapy.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Oclacitinib maleate successfully treated alopecia in Andean bears.

The herbal preparation may help manage alopecia by reducing inflammation and boosting the immune response.

A specific RNA molecule blocks hair growth by affecting a protein related to hair loss conditions.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Apremilast may help treat lichen planopilaris and frontal fibrosing alopecia when other treatments fail.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

The S1PR 1&4 modulator may effectively treat alopecia areata by reducing hair loss and immune cell activity.